GLOBAL PHARMACEUTICAL LEADER SETS SIGHT ON SUSTAINABLE FUTURE FOR THE SECTOR BY SETTING CHALLENGING SBTI NET ZERO TARGET
BASILDON, England, June 6, 2023 /PRNewswire/ -- Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced increased targets to divert 40% of its air shipments to sea in 2023, and 75% by the end of 2028.
- Pharmanovia has made the pledge as it revealed the significant progress made towards achieving its ambitious science-backed ESG initiatives in its new Sustainability Report.
- This initiative demonstrates Pharmanovia's role as an industry leader on carbon reduction and follows a recent report which stated just 16 of 500 pharmaceutical companies measured their entire Scope 3 emissions.
- Pharmanovia's Net-Zero goals have been validated by the Science-Based Target Initiative (SBTi).
- "Our purpose is to improve the lives of patients globally, which is why setting meaningful targets to reduce our environmental impact is critical, to build a sustainable future for patients and the sector.